Serum soluble lymphocyte activation gene‐3 as a diagnostic biomarker in Parkinson's disease: A pilot multicenter study
Autor: | Gang Wang, Gen Li, Sheng-Di Chen, Shi-Shuang Cui, Pingchen Zhang, Yi-Xi He, Yi-Qi Lin, Juan-Juan Du, Shi‐Hua Liu, Jie Meng |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
0301 basic medicine medicine.medical_specialty Parkinson's disease Essential Tremor Disease Lymphocyte Activation Gastroenterology Pathogenesis 03 medical and health sciences 0302 clinical medicine Antigens CD Internal medicine medicine Humans Pathological Essential tremor business.industry Neurodegeneration Area under the curve Parkinson Disease Middle Aged medicine.disease Lymphocyte Activation Gene 3 Protein Phenotype 030104 developmental biology Neurology Biomarker (medicine) Female Neurology (clinical) business Biomarkers 030217 neurology & neurosurgery |
Zdroj: | Movement Disorders. 34:138-141 |
ISSN: | 1531-8257 0885-3185 |
DOI: | 10.1002/mds.27569 |
Popis: | Objective Lymphocyte activation gene-3 (LAG-3) could mediate pathological α-synuclein transmission in neurodegeneration and may be involved in the pathogenesis of Parkinson's disease (PD). The aim of the present study was to explore soluble LAG-3 (sLAG-3) as a potential diagnostic biomarker for PD. Methods Serum sLAG-3 concentrations were measured by a quantitative ELISA for patients with PD, essential tremor (ET) and age- and sex-matched controls. The relationships between sLAG-3 and clinical phenotype were assessed via correlation analysis and logistic regression. Results Serum sLAG-3 levels in patients with PD were significantly higher than those in ET patients and age- and sex-matched controls. The area under the curve of serum sLAG-3 in differentiating PD from age- and sex-matched controls was 0.82. Serum sLAG-3 was associated with non-motor symptoms and excessive daytime sleep. Conclusion sLAG-3 is a candidate novel biomarker for PD. © 2018 International Parkinson and Movement Disorder Society. |
Databáze: | OpenAIRE |
Externí odkaz: |